EuroPCR 24: Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY

Published: 21 May 2024

  • Views:

    Views Icon 123
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.

The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary intervention (PCI). Within this patient group, 40% are expected to be affected by multivessel disease, and 30% by acute coronary syndrome.

Interview Questions:

  1. What is the reasoning behind this study?
  2. Could you tell us a bit more about the Abluminus DES+ SES?
  3. What was the patient population and study design?
  4. What are your key findings?
  5. What are your take-home messages for clinicans?
  6. What are the next steps?

Recorded onsite at EuroPCR Conference, Paris, 2024.

Editor: Jordan Rance
Video Specialists: Dan Brent, 
Interviewer: Liam O'Neill


You must be to comment. If you are not registered, you can register here.